Achievements
Present ~ 2016
- 2024
-
Fexuclue’s cumulative sales surpassed KRW 100 billion (24.May)
-
Phase 3 trials of Atopic Dermatitis for Dogs treatment ‘DWP212525’
approved
-
Phase 3-3(VELOS-4) trials begin for dry eye syndrome treatment
‘HL036’ in the United States
-
V-Olet has been approved in Hainan, China and the Philippines
(December 2024)
- 2023
-
License-out of a first-in-class PRS inhibitor Bersiporocin in the
Greater China region
- Codevelopment of anti-cancer treatment
-
Exclusive licensing agreement for development and commercialization
of Anti-Cancer Drug Generic DWJ108U in the U.S
- 2022
-
Phase 3 topline results announced for enavogliflozin, both for
monotherapy and combination therapy with metformin
-
Investigational new drug (IND) Phase 2 study approved for ‘DWP708’
EGF cream
-
Joint research MOU with Pin Therapeutics for new drugs using protein
lysis technology
-
Successful completion of Phase 3 trials for three-drug combination
therapy of enavogliflozin, a new diabetes treatment
-
Fexuclue receives a Korea New Drug Development Award: A Grand Prize
in the area of new drug development
- Phase 3 trials for enavogliflozin approved in China
-
Concluded an MOU with the Seoul National University Hospital for the
establishment of infrastructure for restorative medicine and
clinical research on advanced biologics
-
New drug development agreement signed with KB Biomed to develop a
modified treatment for osteoporosis using the technology for the
oral administration of protein
-
Application for marketing approval of Fexuclue Tabelt, a new
treatment for GERD, filed in the Philippines, Indonesia, Thailand
and four countries in Central and South America
- Approval of domestic new diabetes drug No. 36 Envlo
-
Phase 3 clinical trial of Nabota for chin reduction successfully
carried out for the first time in the world
-
MOU for cooperation signed with DCGen for breast cancer symptom
prediction kit
-
Marketing approval obtained in Saudi Arabia and Ukraine for Nabota
-
Declared the vision of ‘Global No.1 in Pharmaceutical Preparations
by 2030’: Increased concentration on promising preparation
technologies and open collaboration
-
Multinational Phase 2 trials begin for DWN12088, a new treatment for
idiopathic pulmonary fibrosis
-
MOU signed with Cutis Bio for the development of
environment-friendly, sustainable drug substances and their
commercialization
-
Joint development agreement signed with Sky Therapeutics for
development of percutaneously absorbed treatments based on
solubilization technology
-
Stem cell CDMO agreement signed with Research Institute of Hearing
Enhancement of Yonsei University and Affyxell therapeutics
- Fexuclue Tablet, a new GERD treatment, is released
-
Daewoong Rosuvastatin Tablet 2.5mg Low-Volume obtains marketing
approval
-
DWN12088 becomes the first new drug for idiopathic pulmonary
fibrosis to be designated by FDA for the fast-track approval process
-
Obtained permit from the Ministry of Food and Drug Safety for an
advanced cell product treatment facility and for regenerative
medicine
-
Selected as an R&D project (development of cell treatment products)
by the Korean Fund for Regenerative Medicine
-
Phase 1 trials completed for IVL3001, a continuously sustained
long-term injection product for the treatment of alopecia areata, in
Australia
-
Phase 1 trials in the United States for the new drug for autoimmune
disease treatment approved by FDA
-
‘Fexuclue’ acquires gastritis as an additional indication after a
month of its release
-
Phase 2 trials of botulinum toxin for cervical dystonia successfully
completed in the United States
- Nabota launched in Europe (product name in the UK is Nuceiva)
-
High-volume dexamethasone for oral administration approved in Korea
for the first time, as “Dexa High Tablet"
-
Crezet a low volume, a combination drug (containing rosuvastatin)
for hyperlipidemia, is released, expanding the lineup of treatment
products for abnormal lipidemia
-
Fexuclue obtains marketing approval from the Food and Drug
Administration of the Philippines
- Approval of Vemliver Tab.
-
Selected as an R&D project by the Korea Drug Development Fund (Phase
2 clinical trials of DWN12088 for idiopathic pulmonary fibrosis)
- 2021
-
Received government funding for manufacturing equipment of COVID-19
treatment drug candidate DWRX2003
-
Contracts signed for the entry of Fexuprazan, a treatment for
gastroesophageal reflux disease (GERD), in US, China and 6 Middle
East markets
- Obtained approval for advanced biologics manufacturing
-
V-Olet, an injection to reduce excessive jaw fat has been released
-
Joint R&D with OncoCross to discover new indications for
enavogliflozin and DWN12088
-
Announcement of Phase 1 clinical trial results of DWN12088 in
Australia, the first PRS-inhibiting pulmonary fibrosis treatment in
the world
-
Pulmonary fibrosis treatment ‘DWN12088’ received additional
designation from US FDA as a rare drug
-
Contract signed with D&D Pharmatek to develop orally administered
peptide and protein preparations
-
Phase 3 topline results of botulinum toxin product Nabota announced
in China
-
IVL3001, a continuously sustained long-term injection product for
the treatment of alopecia areata, enters Phase 1 clinical trials in
Australia
-
Fexuclue tablet, a new treatment for GERD, obtained marketing
approval in Korea
- Application filed in China for sales approval of Nabota
- 2020
-
Developed COVID-19 treatment and selected for a government-sponsored
project
-
Daewoong Pharmaceutical’s Olostar was listed in the 2020 National
R&D Excellence Top 100.
-
Novel diabetes drug Enavogliflozin designated for expedited review
for the first time in Korea and conducted a phase 3 clinical trial
-
Registered as a bio-pharmaceutical accelerator, and sign an MOU with
Gyeongsangnam-do, Gimhae, and Inje University
-
Established iN Therapeutics, a drug discovery company (spun off from
Daewoong Pharmaceutical)
-
Selected as a company to be supported by the Ministry of Food and
Drug Safety (MDFS) for Quality by Design (QbD)
-
Independently developed botulinum toxin Nabota obtained marketing
authorization in Taiwan and Brazil
-
Obtained halal certification for Easyef Topical Solution and Epodion
through Daewoong Infion, a joint venture in Indonesia
-
Concluded agreements with Mexico and Brazil to export the next-gen
gastroesophageal reflux disease drug Fexuprazan
-
Established AffyXell Therapeutics, a joint venture specializing in
cellular therapeutics, with the British biotech company Avacta
- 2019
-
Acquired the international standard ISO 9001 certification for a
quality management system (QMS)
-
Received the Minister’s Award (Ministry of Science and ICT) as an
institute of outstanding research note management
-
Completed phase-3 clinical trial on Fexuprazan, a next-generation
drug for gastroesophageal reflux
-
Awarded by the government as an outstanding innovative
pharmaceutical company
-
DWN12088, a new drug for pulmonary fibrosis, designated as an orphan
drug by the USFDA
-
Urusa 300mg obtained indication for prevention of postgastrectomy
cholelithiasis, being the first in the world
-
Officially launched Jeuveau, an internally developed botulinum
toxin, in the US
-
Launched Olomax, a compound of three agents (olmesarta, rosuvastatin
and amlopidine)
-
Phase-3 clinical trial result of Nabota in the US published in an
SCI-grade international journal
-
DWN12088, a new drug for pulmonary fibrosis, selected for the
inter-governmental support project
-
Internally developed botulinum toxin approved by USFDA, being the
first in Asia
- 2018
-
Nabota obtained indication for eye wrinkles as the first botulinum
toxin in Korea
-
DWP14012, a new drug for gastroesophageal reflux, selected for
inter-governmental support project
- 2016
- Completed construction of the Daewoong Bio Center
- Meropenem Inj, an antibiotic, approved by the USFDA
2015 ~ 2011
- 2015
-
Olostar won the Technology Award for new drug development at the
16th Korea New Drug Award (KNDA)
-
Began joint development in the field of antibody through M&A with
HanAll BioPharma
- 2014
-
Received a Prime Minister Citation in the science and technology
category of the Korea New Growth Management Awards
-
Won the Technology Award for new drug development at the 15th Korea
New Drug Award (KNDA)
-
Nabota selected as a World Class Product of Korea by the Ministry of
Trade, Industry and Energy (MOTIE) and the Korea Trade-Investment
Promotion Agency (KOTRA)
- Released Nabota, a botulinum toxin, in Korea
-
Released Olostar, a new drug compound of olmesartan and rosuvastatin
- 2013
- Won the 2013 Innovative Pharmaceutical Company Award
- 2012
- Caretropin Pen won the 2011-2012 World Star Award
-
Selected for World Class 300, a global business development project
- Selected as an Innovative Pharmaceutical Company
- 2011
-
Caretropin Inj. received the Minister’s Award (Ministry of Knowledge
Economy)
2010 ~ 2001
- 2008
-
Easyef acquired the International Nonproprietary Name (INN)
certified by the World Health Organization (WHO) as the first in the
world
- 2005
-
CoenzymeQ10 won the Minister’s Award (Ministry of Health and
Welfare) at the Outstanding Technology Contest of the Health
Industry Technologies Exposition Korea
- CoenzymeQ10 won the Jang Yong-shil Award
- Released Luphere, an anticancer agent
- 2003
-
Succeeded in developing CoenzymeQ10, being the second in the world
-
Easyef Topical Solution won second prize at the Korea New Drug Award
(Korea Drug Research Association: KNDA)
- 2002
-
Easyef Topical Solution awarded as one of 100 Outstanding Patented
Products
- 2001
-
Released Easyef Topical Solution, Korea’s first new
bio-pharmaceutical drug
- Acquired the KT (Korea Good Technology) mark for Easyef
2000 ~ Founded
- 1997
-
Won Outstanding Achievement Award (Korean Intellectual Property
Office) for the patented technology of Easyef
- 1987
-
Received the Iron Tower Order of Industrial Service Merit in the
science and technology category on the 1st Science Day
- Acquired the first genetic engineering patent in Korea
- 1983
- Established Daewoong Central R&D Institute
- 1974
- Established Subsidiary Pharmaceutical Research Center
